I'm excited to be speaking at @RNID's Hearing Therapeutics Summit 2025, which is helping to speed the development of therapeutics for hearing loss and tinnitus. With a strengthening link between age related hearing loss and the underlying aging process, hearing loss has become a

AI Virtual Cell vs Linear Model—who wins? 🤖 ⚔️ 📈 Our preprint, entitled "𝘋𝘦𝘦𝘱 𝘓𝘦𝘢𝘳𝘯𝘪𝘯𝘨-𝘉𝘢𝘴𝘦𝘥 𝘎𝘦𝘯𝘦𝘵𝘪𝘤 𝘗𝘦𝘳𝘵𝘶𝘳𝘣𝘢𝘵𝘪𝘰𝘯 𝘔𝘰𝘥𝘦𝘭𝘴 𝘋𝘰 𝘖𝘶𝘵𝘱𝘦𝘳𝘧𝘰𝘳𝘮 𝘜𝘯𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘷𝘦 𝘉𝘢𝘴𝘦𝘭𝘪𝘯𝘦𝘴 𝘰𝘯 𝘞𝘦𝘭𝘭-𝘊𝘢𝘭𝘪𝘣𝘳𝘢𝘵𝘦𝘥

🚀 We’re hiring a Computational Biologist (Toronto) At Shift Bioscience, we’re uncovering the biology of cell rejuvenation to develop safe, effective therapies that reverse cellular aging 🧬 . Our platform integrates single-cell biology and machine learning to identify and

What is the state of research on the emerging grand challenge of virtual cell modeling? 1/n https://t.co/lOm7d8nd0g

Do deep generative models in single-cell omics really work for perturbation prediction? Some benchmark studies say yes: 🔗 https://t.co/gFYx4SMHXQ 🔗 https://t.co/oBR3p5AetT Others say no: 🔗 https://t.co/KhgEIgKIeD 🔗 BMC Genomics: https://t.co/X1OkXeaErB To move beyond this

Are you trying to build a so-called AI virtual cell? 🔬 Yet ... the mean still outperforms your perturbation-response prediction model. 😮‍💨 Our paper— just accepted to the 𝗚𝗲𝗻𝗕𝗶𝗼 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 @ 𝗜𝗖𝗠𝗟 —dives into 𝘸𝘩𝘺 the mean excels and what you can do about it.

RT @dives86: @ShiftBioscience proposes an improved ranking system for virtual cell models to accelerate gene target discovery and drive rej…

🆕 New LEVITY episode is live! Why tune in? Because a 24-person Cambridge startup may have beaten the billion-dollar OSK race with a single gene found by AI-powered virtual cells - and the early data look game-changing. (Links as always below.) Just about the hottest thing in

Thankyou @peterottsjo and @DrPatrickLinden for hosting me on the LEVITY @reachlevity podcast to discuss our preprint 'A single factor for safer cellular rejuvenation' and beyond!

RT @dives86: @SheekeyScience breaks down the @ShiftBioscience preprint 'A single factor for safer cellular rejuvenation' highlighting both…

Genuine epigenetic rejuvenation in primary cells has long been the holy grail. A groundbreaking preprint reveals that over-expression of a single (secret) gene overcomes this barrier: greatly reduced age estimates across in fibroblasts and keratinocytes according to validated

Single-gene rejuvenation target promises safer cell age reversal @ShiftBioscience #longevitybiotech #aging https://t.co/67fdGF4FBe

Rare moments make you stop, stare, and imagine their future impact. I’m thrilled to share one of those moments from our work at @ShiftBioscience. Over the last few years, the data often felt unreal. Today we compare the single-gene SB000 (Shift Bioscience 000) with the

RT @dives86: The dream of waking up in the near future and being substantially younger at a cellular level is something I have the rare pri…

I’m excited to welcome Lord David Prior and Sir Tony Kouzarides to the team at @ShiftBioscience! Joining as Chair of the Board, David brings a wealth of Board experience, including as Chairman of NHS England, to support the Company’s long term mission to comprehensively reverse

I'll be speaking at Founders Longevity Forum in London on 10th June at OXO2! Let’s connect in London — whether you're building something new in Longevity biotech, investing in the future, or just curious about where the field is going next. Register your interest here:

I’m excited to be part of a #SynBioBeta2025 panel discussing breakthroughs in epigenetic reprogramming and how this could transform Longevity biotech. Let’s connect in San Jose — whether you're building the next big thing in Longevity biotech, investing in the future, or just

1/ We're thrilled to announce Shift Bioscience @ShiftBioscience as a sponsor of Vitalist Bay - our 8-week longevity zone dedicated to combating aging at the cellular level using groundbreaking AI technology. 🔬🧬💻

I’m excited to welcome Dr Jill Reckless and Dr Laurence Reid @laurence_reid to the Shift Bioscience team as Translation Advisor and Non-Executive Director respectively, to help advance our pipeline of rejuvenation therapeutics! Aging mechanisms are common to the majority of

Shift Bio is leading the way in using foundation models for rejuvenation research! Excited to see the breakthroughs they’ll bring in the years ahead!